64 results about "Menopause present" patented technology

Drospirenone for Hormone Replacement Therapy A pharmaceutical composition comprising as a first active ingredient an estrogen, such as estradiol or estradiol valerate, in sufficient amounts to treat disorders and symptoms associated with deficient endogenous levels of estrogen in women, and as a second active ingredient 6beta,7beta; 15beta; 16beta-dimethylene-3-oxo-17alpha-preg-4-ene-21,17-carbolactone (drospirenone, DRSP) in sufficient amounts to protect the endometrium from the adverse effects of estrogen is useful for, amongst others, treating peri-menopausal, menopausal and post-menopausal women. This composition may be used for hormone replacement therapy and may be administered as a multi-phased pharmaceutical preparation. This combination therapy may comprise continuous, sequential or interrupted administration, or combinations thereof, of DRSP and estrogen, each optionally in micronized form.

The present invention relates to a method for stimulating collagen synthesis and/or KGF expression, and more particularly, to a method for stimulating collagen synthesis and/or KGF expression using the AIMP1 or its fragment. The AIMP1 or its fragment can be effectively used for the stimulation of collagen synthesis and/or KGF expression in a subject in need thereof, the treatment of skin aging in the subject, the treatment of the flaccid and/or wrinkled skin in the subject, the promoting the smoothing and/or firming of the skin in the subject, the treatment of adverse cutaneous effects of menopause in the subject, and the treatment of adverse effects of menopause on the collagen.

One aspect of the present invention relates to pharmaceutical compositions containing two or more active agents that when taken together can be used to treat, e.g., menopause, mood disorders, anxiety disorders, or cognitive disorders. The first component of the pharmaceutical composition is a sedative eszopiclone. The second component of the pharmaceutical composition is O-desmethylvenlafaxine. The present invention also relates to a method of treating menopause, perimenopause, mood disorders, anxiety disorders, and cognitive disorders.

Novel methods for treating or reducing the likelihood of acquiring symptoms or diseases due to the menopause, in postmenopausal women, particularly osteoporosis, vaginal atrophy and dryness, hypogonadism, diminished libido, skin atrophy, connective tissue disease, urinary incontinence, breast, endometrial, ovarian and uterine cancers, hot flashes, loss of muscle mass, insulin resistance, fatigue, loss of energy, aging, physical symptoms of menopause, in susceptible warm-blooded animals including humans involving administration of a sex steroid precursor are disclosed. Said method comprising novel ways of administering and dosing dehydroepiandrosterone (DHEA) in order to take advantage of positive androgenic effects in the vaginal layers lamina propia and/or the layer muscularis, without undesirably causing systemic estrogenic effects in order to avoid the risk of breast and uterine cancer. Pharmaceutical compositions for delivery of active ingredient(s) useful to the invention are also disclosed.

An extract of cimicifuga rhizome, its preparing process, and its medicine are disclosed. Said extract can be used to prepare the medicine or health-care food for treating the diseases caused by stimulin disorder of woman, such as climacteric syndrome, and promoting bone generation and absorption.

The medicine for treating hyperplasia of mammary glands consists of 19 kinds of Chinese medicinal materials, including bupleurum root, angelica, etc. as basic components, and has other components added to adapt various disease symptoms caused by different causes, such as getting angry, menstruation, climacterium and tumor. The medicine is ultraviolet ray sterilized before grinding.

The present invention provides transmucosal pharmaceutical or nutraceutical compositions and methods for enhancing transmucosal delivery of pharmaceutical and nutraceutical ingredients through use of methylsulfonylmethane (MSM) as a transmucosal delivery enhancer. In particular, the invention provides transmucosal compositions comprising an active agent selected from a non-steroid anti-inflammatory drug (NSAID); an analgesic; a migraine medication; a menopause medication; a sleep disorder medication; an erectile dysfunction medication, an appetite suppressant, a vitamin, a food supplement and a macromolecule. In certain particular exemplary formulations the appetite suppressant is DL-phenylalanine, and the vitamin is B12.

The invention relates to medicinal use of leonurine for menopause disease, and in particular provides the medicinal use of the leonurine or pharmaceutical salts thereof for preventing or treating menopause syndrome and menopause syndrome related diseases.

Disclosed are compositions and methods for treating symptoms associated with menopause and/or perimenopause. The compositions are based on a combination of concentrated extracts containing black cohosh, ginseng, red clover, soy isoflavones and St. John's wort, in the form of active compounds of these extracts. The treatment regimen, entail orally administering to a human subject suffering from symptoms of menopause and/or perimenopause, an effective dosage in effective amounts of the noted composition.

The invention discloses application of all-cannabinoid in preparation of drugs for treating depression. The all-cannabinoid is prepared by uniformly mixing, by weight, 0.3-99.7 parts of an industrial hemp seed extract with 99.7-0.3 parts of industrial cannabinoids. The all-cannabinoid has the obvious relieving effect on the symptoms such as secondary learning memory deterioration of the depression and can be used for preparing the drugs for treating various depression symptoms including endogenous depression, reactive depression, latent depression, secondary depression caused by drugs, climacteric or postnatal depression, depression induced by cerebral trauma or stroke, diabetes-complicated depression and depressive neurosis and used for preparing the drugs for treating the symptoms such as secondary learning memory deterioration and anhedonia which are caused by the depression, and the effect of the all-cannabinoid is better than that of cannabidiol. The all-cannabinoid can be prepared into the clinical drugs of various dosage forms through a conventional preparation method and is convenient to use.

The present invention is one kind of medicine composition for treating female climacteric syndrome, endocrine and cardiac and cerebral vascular diseases and its preparation process. The medicine composition is prepared with nine kinds of Chinese medicinal materials, including conic gymnadenia tuber, silverweed cinquefoil root, mango stone, wolfberry fruit, fragrant rhododendron leaf, etc. Through water extracting, alcohol extracting, decompression concentrating, vacuum drying and other steps, the medicine composition is prepared into different pharmaceutically acceptable preparations. The medicine composition has obvious curative effect on the said diseases.

The health care pill for women in climacteric period is prepared with 14 kinds of Chinese medicinal materials, including figwort, red sage, ophiopogon root, rehmannia root, prepared rhizome of rehmannia, etc. The medicine is constituted based on the Chinese medicine theory of tranquilizing, calming and suppressing the sthenic Yang, nourishing the heart and benefiting Yin, and with the Chinese medicinal materials with the corresponding functions. The medicine is prepared into orally taken medicine pill for nourishing blood, tonifying heart and regulating women's internal secretion, and has high and fast curative effect and no side effect.